Success examples
Super-Enhancer Dysregulation in Rhabdoid Tumor Cells Is Regulated by the SWI/SNF ATPase BRG1

Jones C. A., Wang J., Evans J. R., Sisk H. R., Womack C. B., Liu Q., Tansey W. P., Weissmiller A. M.

Cancers (Basel). 2024, 16(5):916.

SMARCA2/4 PROTAC
DOI
PubMed
Success examples
Enhancement of Intracellular Cholesterol Efflux in Chondrocytes Leading to Alleviation of Osteoarthritis Progression

Lee G., Yang J., Kim S. J., Tran T. T., Lee S. Y., Park K. H., Kwon S. H., Chung K. H., Koh J. T., Huh Y. H., Seon J. K., Kim H. A., Chun J. S., Ryu J. H.

Arthritis Rheumatol. 2025, 77(2):151-162.

LOX-1 inhibitor
DOI
PubMed
Success examples
Fluorophore-Labeled Pyrrolones Targeting the Intracellular Allosteric Binding Site of the Chemokine Receptor CCR1

Toy L., Huber M. E., Lee M., Alonso Bartolomé A., Ortiz Zacarías N. V., Nasser S., Scholl S., Zlotos D. P., Mandour Y. M., Heitman L. H., Szpakowska M., Chevigné A., Schiedel M.

ACS Pharmacol Transl Sci. 2024, 7(7):2080-2092.

CCR1 antagonist
DOI
PubMed
Success examples
Functional characterization of pathway inhibitors for the ubiquitin-proteasome system (UPS) as tool compounds for CRBN and VHL-mediated targeted protein degradation

Schwalm M. P., Menge A., Elson L., Greco F. A., Robers M. B., Müller S., Knapp S.

ACS Chem Biol. 2025, 20(1):94-104.

BET PROTAC
DOI
PubMed
Success examples
Sex Matters–Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer

Schulz B., Leitner E., Schreiber T., Lindner T., Schwarz R., Aboutara N., Ma Y., Ecobar H. M., Palme R., Hinz B., Vollmar B., Zechner D.

Cancers (Basel). 2024, 16(10):1901.

SOS1::KRAS inhibitor
DOI
PubMed